A ventricular aneurysm is a dreaded myocardial infarction complication that develops in post-myocardial infarction's remodeling phase. There can be true aneurysms and false aneurysms; the latter constitute only of pericardial layer; it lacks myocardial and epicardial elements [1]. It has been observed that the incidence of true aneurysms of the heart following myocardial infarction is approximately 10% [2]. Aneurysms exhibit either paradoxical systolic expansion, total akinesis, or both [3]. Transmural myocardial infarction results in the weakening of ventricular walls leading to ventricular aneurysms. Other causes of a false aneurysm can be cardiac surgery, chest trauma, congenital heart disease, and tumor invasion [1,4]. Presenting symptoms range from chest pain, palpitations, dyspnea, and syncope to nonspecific symptoms, and up to 10% may be asymptomatic [4]. The presenting symptoms in false aneurysms are nonspecific, and diagnosis is often delayed. We present a case of a male with a true ventricular aneurysmfound dead inside his room.
A 32-year-old male with an alleged history of being found down at his residence on Mar 15, 2021, at around 1:00 AM by co-workers at Timli, Tehri Garhwal, Uttarakhand. He used to work with a construction company as a laborer at the construction site. He was ill on and off and used to take some medicines from the local medical shop, as told by his co-workers. The subject belonged to low socioeconomic status and had no recorded past medical or surgical history.
On post-mortem examination, the body was a moderately built male with a congested face and eyes with cyanosis over fingernails. On dissection, the lungs and thoracic cavity showed 400 ml of straw-colored fluid on the right side and 390 ml on the left side. The right lung weighed 720 gm and the left - 460 gm; both the lungs were congested, and on the cut section, pinkish frothy fluid was present in both lungs. The pericardium was intact; 210 ml of serous thin pinkish fluid was present on the opening. The heart weighed 460 gm. Grossly enlarged heart with thinning out of the anterior wall over the middle part of the interventricular septal area with a diameter of 3 cm (Figure 1A) was surrounded by ecchymotic patches and petechial hemorrhages over the anterior, anterolateral, and posteroinferior surface (Figure 1B).There were multiple petechial hemorrhages at places over the surface of the heart. Coronaries showed left anterior descending artery with atheromatous changes with calcification causing >98% stenosis, 1.5 cm distal to origin. The right coronary artery showed atheromatous changes with calcification causing 95% stenosis. The left circumflex artery showed athermanous changes with calcification causing 60-70% stenosis.
On histological examination, features of myocardial infarction over the left ventricle wall with severe atherosclerosis of the left anterior descending artery were present. The left ventricular bulge showed thinned-out myocardium with a loss of muscle fibers at places, suggesting a true ventricular aneurysm (Figure 2A). Higher magnification shows endomyocardial with dilated vessels, and haphazard myocardial arrangement as the heart is in the remodeling phase (Figure 2B).
There were necrosed myocardiocytes with areas of fibrosis and granulation tissue (Figure 3A). Histological examination also revealed dense inflammation and edema within a ventricular wall (Figure 3B).
A cross-section of the left anterior descending artery and left coronary artery showed luminal occlusion by thrombosis and atheroma (Figure 4).
A restricted hematoma dissecting into a transmural infarct is a reason for a false aneurysm. Through a tiny aperture, it interacts with the left ventricle. False aneurysms have a pericardium and mural thrombus wall without recognizable epicardial or myocardial features. Both true and false heart aneurysms are consequences of myocardial infarction, although they can have radically different etiologies, effects on ventricular function, diagnostic findings, complications, pathological findings, and treatment. A genuine ventricular aneurysm is brought on by the gradual weakening of a section of the ventricular wall after a transmural infarction, and the thinned-out area may gradually expand untilit significantly outgrows the infarct's initial surface area. The end result is a non-contractile, maybe expansile segment that is a part of the circumferential wall borders of the left ventricle [1]. Pericardium that is adhered to the underlying epicardium makes up the wall of genuine true aneurysms; fibrous connective tissue of the infarcted cardiac muscle frequently lies beneath this. A false aneurysm is formed by hemorrhagic dissection into the wall of transmural infarction [1].
Although a left aneurysm is frequently suspected clinically, often left ventricular cineangiography is typically used to confirm the diagnosis. A fake aneurysm frequently manifests as a distinct cavity thatfills through a tiny orifice during systole and returns back to the ventricle during diastole [1]. The myocardium is at a mechanical disadvantage when the size of an actual aneurysm exceeds 20 to 25% of the ventricle area, which can only be overcome by the heart by dilating the ventricular cavity [1,3]. The false aneurysm does not interfere with muscle function but acts to unload the ventricle during systole, almost like bicuspid valve incompetence, which will reduce flow and, indirectly, end in left ventricular dilatation. False aneurysms differ in their gross and microscopic pathology and operative management. Indications for operative intervention are equivalent to those for a true aneurysm; however, since they need a bent toward rupture, which by true aneurysms, prophylactic repair may be a further indication for operation even within the asymptomatic patient [1].
An aneurysm is a rare complication of myocardial infarction. Transmural myocardial infarction is the most common cause of a false aneurysm [4]. The rupture is sealed by pericardial attachments, forming a hematoma, thrombus, or scar tissue, forming an aneurysm [4-6].If left undiscovered, the fake aneurysm wall, which is only made up of fibrous tissue or pericardium and lacks the true layers of endocardium and myocardium, has a very high mortality rate [4,7]. These aneurysms require prompt detection and treatment because they are more likely to burst [4,6]. Congenital heart disease, chest injuries, tumor invasion, cardiac surgery, and endocarditis are some other etiologies causing aneurysms [4,5,8,9].
The incidence of a false ventricular aneurysm is 0.1% in patients with myocardial infarction and 0.8% in patients who have undergone mitral valve replacement surgery [4,10,11]. The majority of patients were White (75%), and male (67%), and the mean age at presentation was 60 years, according to one study [4,12]. Untreated left ventricular false aneurysms have a 30-45% likelihood of rupturing [4,13].
Although it can develop up to 12 months after a myocardial infarction, a left ventricular false aneurysm typically develops within three to 14 days of the myocardial infarction [4,9]. Increased macrophage activity in the infarcted tissue as a result of the inflammatory process causes remodeling and tissue thinning of the necrotic myocardium.The sealed wall rupture as a false aneurysm at that time as a result of the inflammatory and prothrombotic state [4,14].
Up to 10% of patients may be asymptomatic, and some may present with several vague symptoms. Chest discomfort, palpitations, dyspnea, and syncope are common symptoms in certain people; other patients may also experience indistinct symptoms such as coughing, fever, disorientation, shoulder or back pain, dysphagia, congestive heart failure, and stroke [4,11]. Surgery is the only definitive treatment for left ventricular false aneurysms. According to various research, asymptomatic patients with an accidental diagnosis of a false aneurysm, which was smaller than 3 cm in size, and patients who are not medically qualified for surgery are managed non-surgically [4,11]. Given their ability to resemble false aneurysms, true left ventricular aneurysms deserve consideration. When compared to false aneurysms, true aneurysms are a very common problem that affects 10% to 35% of patients [4,14]. Preoperatively, it can frequently be challenging to distinguish between aneurysms. A true aneurysm, as compared to a false one, contains all three layers of the myocardial wall and is characterized by contractile dyskinesia or a paradoxical bulge with a left ventricular diastolic contour area, which lowers the ejection rate [4]. True aneurysms usually occur in the anterior or apical region, while false aneurysms more commonly occur in the posterior region. Mostly true, aneurysms are non-contractile and have a thin myocardium [11].
Due to the false aneurysm sac's inherent fragility, it can cause dyskinetic heartbeats that can result in arrhythmias, clot formation, and even heart failure[4,5]. A false aneurysm's common sequelae are the adherent sac's rupture [15].
The likelihood of a left ventricular (LV) pseudoaneurysm increases following an inferior myocardial infarction. Despite typical presentations like heart failure, embolism, and arrhythmias, some aneurysms are unexpectedly stable and go unnoticed for years [16]. Differentiating an LV pseudoaneurysm from a true aneurysm is necessary because rupture can be prevented with early surgical intervention [16].
Among all the late complications of acute myocardial infarction, a left ventricular wall aneurysm is uncommon and possibly like a hidden bomb, so one must be vigilant to the presenting symptoms related to cardiac performances or any sudden change in the hemodynamic stability of the patient. Advances in radiological imaging have increased the capacity to differentiate cardiac pseudoaneurysms from different pathologies. Most pseudoaneurysms, specifically if acute or related to symptoms, require surgical treatment to lessen the chances of rupture; if treated adequately and promptly, it avoids sudden deaths.
See the original post:
Myocardial Infarction With Ventricular Wall Aneurysm: A Case Report - Cureus
- Managing Right Ventricular Failure in PAH: An Algorithmic Approach | Advances in ... - April 13th, 2018 [April 13th, 2018]
- What Is the Ejection Fraction? - Verywell Health - May 12th, 2018 [May 12th, 2018]
- Ventricular septal defect - Wikipedia - June 21st, 2018 [June 21st, 2018]
- Heart Failure Medication: Beta-Blockers, Alpha Activity ... - July 7th, 2018 [July 7th, 2018]
- Acute Management of Pulmonary Embolism - American College ... - July 17th, 2018 [July 17th, 2018]
- Ventricular Remodeling | Profiles RNS - July 24th, 2018 [July 24th, 2018]
- Left ventricular hypertrophy - Wikipedia - August 20th, 2018 [August 20th, 2018]
- Ventricular Remodeling Surgery (SVR) - September 24th, 2018 [September 24th, 2018]
- Left Ventricular Remodeling in Heart Failure | JACC ... - November 25th, 2018 [November 25th, 2018]
- Ventricular dysfunction in heart failure - Britannica.com - December 25th, 2018 [December 25th, 2018]
- TIMI Study Group - LEADERSHIP - January 31st, 2019 [January 31st, 2019]
- Ventricular Remodeling Procedure | Main Line Health ... - February 24th, 2019 [February 24th, 2019]
- BioLineRx Ltd. (BLRX)'s Financial Results Comparing With Coherus BioSciences Inc. (NASDAQ:CHRS) - Stocks Beat - September 18th, 2019 [September 18th, 2019]
- Reviewing Aeterna Zentaris Inc. (AEZS)'s and BioLineRx Ltd. (NASDAQ:BLRX)'s results - Stocks Beat - September 18th, 2019 [September 18th, 2019]
- Karuna Therapeutics Inc. (KRTX) and BioLineRx Ltd. (NASDAQ:BLRX) Comparing side by side - Stocks Beat - September 18th, 2019 [September 18th, 2019]
- Arbutus Biopharma Corporation (ABUS)'s Financial Results Comparing With BioLineRx Ltd. (NASDAQ:BLRX) - The EN Herald - September 18th, 2019 [September 18th, 2019]
- Cardiac Dimensions touts Carillon TMVR study - Mass Device - September 18th, 2019 [September 18th, 2019]
- New PROVE-HF Data May Reassure Clinicians of Sacubitril/Valsartan Benefit in HFrEF - TCTMD - September 18th, 2019 [September 18th, 2019]
- Cardiac Restoration Systems Market Will Make a Huge Impact in Near Future - Wolf Mirror - September 18th, 2019 [September 18th, 2019]
- Reduce Fmr Study Shows Cardiac Dimensions' Carillon System Significantly Improves Mitral Regurgitation And Slows Worsening Of Heart Failure - TCTMD - September 18th, 2019 [September 18th, 2019]
- Heart Failure Society of America 2019: Virtual Visits, Spironolactone Issues, and Reasons to Worry - DocWire News - September 18th, 2019 [September 18th, 2019]
- LV Reverse Remodeling Not Improved by SGLT-2 Inhibitor - DocWire News - September 18th, 2019 [September 18th, 2019]
- BioLineRx Ltd. (BLRX)'s Financial Results Comparing With Soligenix Inc. (NASDAQ:SNGX) - CryptoCoinsTribune - September 22nd, 2019 [September 22nd, 2019]
- Biolinerx LTD. American Depositary Shares (NASDAQ:BLRX) Could Burn Your Long Portfolio After More Shorts - The MAK Daily - September 22nd, 2019 [September 22nd, 2019]
- Reviewing BioLineRx Ltd. (BLRX)'s and Dicerna Pharmaceuticals Inc. (NASDAQ:DRNA)'s results - CryptoCoinsTribune - September 22nd, 2019 [September 22nd, 2019]
- Comparison of Protalix BioTherapeutics Inc. (PLX) and BioLineRx Ltd. (NASDAQ:BLRX) - MS Wkly - October 19th, 2019 [October 19th, 2019]
- Contrasting of BioLineRx Ltd. (BLRX) and Edge Therapeutics Inc. (:) - MS Wkly - October 19th, 2019 [October 19th, 2019]
- Contrasting of BioLineRx Ltd. (BLRX) and Protalix BioTherapeutics Inc. (NYSEAMERICAN:PLX) - The Broch Herald - November 7th, 2019 [November 7th, 2019]
- BioLineRx Ltd. (BLRX)'s Financial Results Comparing With Cyanotech Corporation (NASDAQ:CYAN) - The Broch Herald - November 7th, 2019 [November 7th, 2019]
- Triple-Gene Announces Completion of Enrollment and Dosing in Phase 1 Trial of INXN-4001, First Multigenic Investigational Therapeutic Candidate for... - November 7th, 2019 [November 7th, 2019]
- Contrasting of BioLineRx Ltd. (BLRX) and Moderna Inc. (NASDAQ:MRNA) - The Broch Herald - December 3rd, 2019 [December 3rd, 2019]
- Edited Transcript of MYOK earnings conference call or presentation 11-Nov-19 1:30pm GMT - Yahoo Finance - December 3rd, 2019 [December 3rd, 2019]
- Cardiac Restoration Systems Market: Key Growth Factors and Industry Analysis 2018 - 2028 - The Market Expedition - December 3rd, 2019 [December 3rd, 2019]
- Velocity Transfer Function In The Right Pulmonary Artery And Impaired | COPD - Dove Medical Press - December 3rd, 2019 [December 3rd, 2019]
- 3 Stocks to Buy Ahead of the Next Market Crash - The Motley Fool - December 3rd, 2019 [December 3rd, 2019]
- Pulmonary Hypertension, Common in TAVR Patients, Linked to Lower Survival - TCTMD - December 3rd, 2019 [December 3rd, 2019]
- Patients With Chemotherapy-Induced Cardiomyopathy Show Improvements in LVEF After Cardiac Resynchronization Therapy - AJMC.com Managed Markets Network - December 4th, 2019 [December 4th, 2019]
- BioVentrix Announces Publication of Positive One-Year Outcomes for Revivent TC System - Yahoo Finance - December 4th, 2019 [December 4th, 2019]
- Cardiac Restoration Systems Market Forecasted To Surpass The Value Of US$ XX Mn/Bn By 2055 2017 2025 - Weekly News Times - December 13th, 2019 [December 13th, 2019]
- The Outer Line: The impact of endurance training on the cardiac health of women - VeloNews - December 13th, 2019 [December 13th, 2019]
- Contrasting of Insmed Incorporated (INSM) and BioLineRx Ltd. (NASDAQ:BLRX) - The CoinGlobalist - December 16th, 2019 [December 16th, 2019]
- CARDIAC RESTORATION SYSTEMS MARKET ANALYSIS TRENDS, GROWTH OPPORTUNITIES, SIZE, TYPE, DYNAMIC DEMAND AND DRIVES WITH FORECASTS TO 2028 - Voice of... - January 13th, 2020 [January 13th, 2020]
- Early Expressed Circulating Long Noncoding RNA CHAST is Associated with Cardiac Contractile Function in Patients with Acute Myocardial Infarction -... - January 13th, 2020 [January 13th, 2020]
- Clinical Phenogroups in Heart Failure With Preserved Ejection Fraction: Detailed Phenotypes, Prognosis, and Response to Spironolactone - DocWire News - January 23rd, 2020 [January 23rd, 2020]
- Increased Long-Term Risk for Venous Thromboembolism After Heart Failure - The Cardiology Advisor - January 23rd, 2020 [January 23rd, 2020]
- Retinoid X receptor alpha is a spatiotemporally predominant therapeutic target for anthracycline-induced cardiotoxicity - Science Advances - February 1st, 2020 [February 1st, 2020]
- Coronary Microvascular Dysfunction Found to Increase Risk for CV Events in Chronic Kidney Disease - The Cardiology Advisor - February 1st, 2020 [February 1st, 2020]
- New Data Confirms Cardiac Dimensions' Carillon System Shows Favorable Long-Term Survival Rate In Patients With Functional Mitral Regurgitation -... - February 26th, 2020 [February 26th, 2020]
- BioVentrix Announces Ralph Stephan von Bardeleben, MD, as Co- Principal Investigator of the REVIVE-HF Clinical Trial - Yahoo Finance - March 5th, 2020 [March 5th, 2020]
- Relationship between histopathological features of aspirated thrombi and long-term left ventricular function in patients with ST-segment elevation... - March 15th, 2020 [March 15th, 2020]
- FierceMedTech Names BioVentrix as One of Its "Fierce 15" Companies of 2019 - Yahoo Finance - March 15th, 2020 [March 15th, 2020]
- Causes and Prevention of Ventricular Remodeling After MI ... - March 16th, 2020 [March 16th, 2020]
- Left Ventricular Remodelling - ECR Journal - April 23rd, 2020 [April 23rd, 2020]
- Cardiac Restoration Systems Market to Make Great Impact in Near Future by 2026 - The Canton Independent Sentinel - June 12th, 2020 [June 12th, 2020]
- Multi-Society Guidelines on the Use of Multimodality CV Imaging in Competitive Athletes - The Cardiology Advisor - June 12th, 2020 [June 12th, 2020]
- Chronic PDE5i Treatment Found to Improve Cardiac Remodeling in Men, but Not Women, With Diabetic Cardiomyopathy - Endocrinology Advisor - June 12th, 2020 [June 12th, 2020]
- Acceleron to Host Conference Call and Webcast to Review Results of PULSAR Phase 2 Trial of Sotatercept Presented at American Thoracic Society 2020... - June 23rd, 2020 [June 23rd, 2020]
- American Heart Association and Barth Syndrome Foundation Partner to Address Rare Disease - PR Web - August 29th, 2020 [August 29th, 2020]
- The Association of Cardio-Ankle Vascular Index (CAVI) with Biatrial Remodeling in Atrial Fibrillation - DocWire News - September 3rd, 2020 [September 3rd, 2020]
- Cardiac Dimensions Announces Australian Therapeutic Goods Administration's Approval of the Carillon System for the Treatment of Functional Mitral... - September 3rd, 2020 [September 3rd, 2020]
- Sep 4 2020 This Week in Cardiology - Medscape - September 5th, 2020 [September 5th, 2020]
- Emerging treatment helps reverse heart failure in some patients - Science Codex - October 27th, 2020 [October 27th, 2020]
- GMAX Biopharm gives first does of anti-body drug treating PAH in phase 1B trial - PRNewswire - October 27th, 2020 [October 27th, 2020]
- North America to Outshine the Global Slowdown in Cardiac Restoration Systems market between 2020 and 2030 - The Think Curiouser - November 12th, 2020 [November 12th, 2020]
- Age-Related Development of Cardiac Remodeling and Dysfunction in Young Black and White Adults: the Coronary Artery Risk Development in Young Adults... - November 25th, 2020 [November 25th, 2020]
- Adiponectin receptor 1 variants contribute to hypertrophic cardiomyopathy that can be reversed by rapamycin - Science Advances - January 13th, 2021 [January 13th, 2021]
- Longer Survival Seen in Heart Failure Stabilized Via Cardiac Resynchronization Therapy - The Cardiology Advisor - April 13th, 2021 [April 13th, 2021]
- Cardiac Dimensions Welcomes Robert White to its Board of Directors - PRNewswire - April 13th, 2021 [April 13th, 2021]
- [Full text] SIRT1 is Required for Exercise-Induced Beneficial Effects on Myocardia | JIR - Dove Medical Press - April 13th, 2021 [April 13th, 2021]
- Role of Pyroptosis in Diabetes and Its Therapeutic Implications | JIR - Dove Medical Press - May 25th, 2021 [May 25th, 2021]
- Epigenetic therapies for heart failure | VHRM - Dove Medical Press - May 25th, 2021 [May 25th, 2021]
- Are you at risk for sudden death, and can it be prevented? - Jamaica Observer - May 25th, 2021 [May 25th, 2021]
- Does a plant-based diet improve cardiac function? Here's the answer - Hindustan Times - June 21st, 2021 [June 21st, 2021]
- Early Use of Sacubitril/Valsartan Linked to Improved Cardiac Function Post AMI - AJMC.com Managed Markets Network - November 5th, 2021 [November 5th, 2021]
- Higher BP, LV Changes Seen in Children Conceived by ART - Medscape - November 5th, 2021 [November 5th, 2021]
- Regional Heterogeneity in Determinants of Atrial Matrix Remodeling and Association with Atrial Fibrillation Vulnerability Post-Myocardial Infarction -... - January 26th, 2022 [January 26th, 2022]
- 4 promising heart failure therapies interventional cardiologists should keep an eye on - Cardiovascular Business - May 7th, 2022 [May 7th, 2022]
- LEXEO Therapeutics Announces Data Presentations at the 25th American Society of Gene & Cell Therapy (ASGCT) Annual Meeting - Yahoo Finance - May 7th, 2022 [May 7th, 2022]
- Ventricular structure and function in hypertensive patients | IJGM - Dove Medical Press - May 7th, 2022 [May 7th, 2022]
- Effects of diabetes mellitus on left ventricular function and remodeling in hypertensive patients with heart failure with reduced ejection fraction:... - May 7th, 2022 [May 7th, 2022]